$9.120
+0.040 (+0.44%)收盤時
價格預測
在 App 中開啟以解鎖更長週期的預測。
RNAC 相似圖表分析預測
Alphio's RNAC stock price prediction model matches the current Cartesian Therapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $9.04 (-0.84%). The 1-week path is $9.21 (+1.02%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
該買進 Cartesian Therapeutics Inc 股票嗎?
Cartesian Therapeutics Inc is a good buy right now due to its recent strategic licensing deal that has driven the stock up over 30%, indicating strong market confidence. The current price is $9.60, which is significantly lower than the analyst price target of $25, suggesting substantial upside potential. Additionally, the company has a gross margin of 100%, showing strong profitability potential on revenues. However, a key risk is the forward P/E ratio of 25.06, indicating that the stock may be overvalued relative to its earnings potential in the near term.
RNAC 股價於 Thursday 收在 $9.12,此前上漲 +0.44%
Cartesian Therapeutics Inc (RNAC) last closed at $9.12, gaining +0.44%. These facts feed the 1-day and 1-week RNAC price prediction above.
預測驅動因素
Cartesian Therapeutics Inc(RNAC)的預測驅動因素綜合了相似的圖表形態、季節性與移動平均線。
Similar patterns
Bearish
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bullish
相似圖表形態
近期走勢與 RNAC 最接近的股票,依相似度排序。
RNAC 季節性分析
Historically the probability of a positive September return for RNAC is 6.82%. January offers the highest probability of a positive month at 85.25%, while September is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。